China moves quickly on ICH E6(R3) Annex 2 with March applicability date

China’s National Medical Products Administration (NMPA) Center for Food and Drug Inspection (CFDI) opened a one-month public consultation on August 11, 2026, on a Chinese translation of ICH E6(R3) Annex 2 and proposed recommendations for its implementation in China.

The consultation comes just over two months after ICH adopted Annex 2 at Step 4 on June 3. The annex provides additional Good Clinical Practice (GCP) considerations for trials incorporating decentralized elements, pragmatic elements and real-world data (RWD), extending the E6(R3) framework to clinical research involving activities outside conventional investigator sites and data generated in routine healthcare settings.

What it covers

The consultation package includes a draft Chinese translation of E6(R3) Annex 2, the original English text, proposed implementation recommendations and a feedback form.

CFDI's implementation recommendation states that clinical trials beginning from March 31, 2026 are subject to E6(R3). The date mirrors an implementation timeline previously established by NMPA in December 2025 for E6(R3), following ICH's adoption of the E6(R3) Principles and Annex 1 in January 2025.

However, Annex 2 did not reach ICH Step 4 until June 3, 2026. Applying the same March 31 date to the newly finalized annex could therefore bring trials that began before Annex 2 was finalized within its scope.

Annex 2 addresses GCP considerations arising from decentralized trial elements, pragmatic trial approaches and the use of RWD. Among other areas, it considers trial activities performed outside investigator sites, digital health technologies, healthcare settings integrated into trial conduct, and the use of existing data sources such as electronic health records and registries.

Why it matters

The proposal signals a rapid move by Chinese regulators to incorporate the latest ICH clinical trial standards into the domestic regulatory framework. ICH finalized Annex 2 on June 3, while CFDI issued its Chinese translation and implementation proposal on August 11.

The proposed March 31 applicability date is particularly notable because it predates the international finalization of Annex 2. If retained in the final implementation recommendation, relevant trials initiated between March 31 and June 3 could potentially fall within the scope of requirements that had not yet reached final ICH form when those studies began.

This could be particularly relevant to sponsors conducting trials in China that incorporate decentralized or pragmatic elements or use RWD. Further clarification may therefore be needed on expectations for trials initiated during this period and on how Annex 2 interacts with China's existing requirements governing clinical trial operations, healthcare data and electronic systems.

China's proposed approach also contrasts with implementation in the EU. The European Medicines Agency adopted Annex 2 in June 2026 but has set January 15, 2027 as its effective date, giving sponsors a substantially longer prospective implementation period.

More broadly, Annex 2 addresses areas of growing importance to clinical development, including trial activities conducted outside traditional sites and the integration of data generated through routine healthcare and digital technologies. China's rapid move toward implementation could therefore have practical implications for how sponsors design and operate newer models of clinical research in the country.

Source attribution

CDE notice published August 11, 2026, via the China Pharmaceutical Information website: https://www.cpi.ac.cn/tggg/qtggtg/202608/t20260811_430424.html

---

Access the AllSci platform to explore the science behind the news.

---

Spot something wrong? Report an issue with this article